429 reports of this reaction
1.4% of all EVEROLIMUS TABLETS reports
#20 most reported adverse reaction
METASTASES TO BONE is the #20 most commonly reported adverse reaction for EVEROLIMUS TABLETS, manufactured by Amneal Pharmaceuticals NY LLC. There are 429 FDA adverse event reports linking EVEROLIMUS TABLETS to METASTASES TO BONE. This represents approximately 1.4% of all 31,530 adverse event reports for this drug.
Patients taking EVEROLIMUS TABLETS who experience metastases to bone should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METASTASES TO BONE is a less commonly reported adverse event for EVEROLIMUS TABLETS, but still significant enough to appear in the safety profile.
In addition to metastases to bone, the following adverse reactions have been reported for EVEROLIMUS TABLETS:
The following drugs have also been linked to metastases to bone in FDA adverse event reports:
METASTASES TO BONE has been reported as an adverse event in 429 FDA reports for EVEROLIMUS TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
METASTASES TO BONE accounts for approximately 1.4% of all adverse event reports for EVEROLIMUS TABLETS, making it a notable side effect.
If you experience metastases to bone while taking EVEROLIMUS TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.